Protease inhibitors for the treatment of hepatitis C virus infection
The hepatitis C virus (HCV) has affected an estimate of 80 million individuals worldwide and is a strain of public health. Around 25–30% of patients in Europe and the US infected with HIV are coinfected with HCV. Despite treatment modalities containing a NS3/4A protease it in combination with pegyla...
Main Authors: | de Leuw, Philipp, Stephan, Christoph |
---|---|
Format: | Article |
Language: | English |
Published: |
German Medical Science GMS Publishing House
2017-11-01
|
Series: | GMS Infectious Diseases |
Subjects: | |
Online Access: | http://www.egms.de/static/en/journals/id/2017-5/id000034.shtml |
Similar Items
-
New hepatitis C therapies in clinical development
by: Vermehren Johannes, et al.
Published: (2011-07-01) -
Hepatitis C treatment: where are we now?
by: Burstow NJ, et al.
Published: (2017-02-01) -
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
by: Childs-Kean LM, et al.
Published: (2019-07-01) -
Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs
by: Allan Peres-da-Silva, et al.
Published: (2012-03-01) -
Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
by: Auda A. Eltahla, et al.
Published: (2015-09-01)